Arrowhead Pharmaceuticals Price Target, Predictions & Analyst Ratings

+0.97 (+1.42 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume537,921 shs
Average Volume1.09 million shs
Market Capitalization$7.21 billion
P/E RatioN/A
Dividend YieldN/A

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Arrowhead Pharmaceuticals in the last 12 months. Their average twelve-month price target is $86.45, predicting that the stock has a possible upside of 24.77%. The high price target for ARWR is $110.00 and the low price target for ARWR is $34.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
TypeToday30 Days Ago90 Days Ago180 Days Ago
ARWR Consensus Rating: BuyBuyBuyBuy
ARWR Consensus Rating Score: 2.802.802.822.73
ARWR Analyst Ratings: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
ARWR Consensus Price Target: $86.45$86.45$84.92$75.50
ARWR Price Target Upside: 24.77% upside17.83% upside15.03% upside29.22% upside

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetDetails
7/2/2021HC Wainwright
Patrick Trucchio
Reiterated RatingBuy$95.00
7/2/2021Piper Sandler
Lower Price TargetOverweight$109.00 ➝ $89.00
6/27/2021SVB Leerink
Reiterated RatingHold
Boost Price Target$90.00 ➝ $110.00
2/8/2021B. Riley
Boost Price TargetBuy$98.00 ➝ $106.00
2/5/2021Chardan Capital
Boost Price TargetBuy$81.00 ➝ $97.00
12/21/2020Robert W. Baird
DowngradeOutperform ➝ Neutral$75.00
12/15/2020UBS Group
Initiated CoverageBuy$95.00
11/24/2020Royal Bank of Canada
Boost Price TargetPositive ➝ Outperform$62.00 ➝ $80.00
11/24/2020Cantor Fitzgerald
Boost Price TargetOverweight$58.00 ➝ $80.00
11/19/2020Smith Barney Citigroup
Initiated CoverageBuy$90.00
Esther Rajavelu
UpgradeMarket Perform ➝ Outperform$58.00
3/17/2020The Goldman Sachs Group
Initiated CoverageNeutral$45.00
2/7/2020Jefferies Financial Group
Boost Price Target$77.00 ➝ $80.00
12/9/2019Piper Jaffray Companies
Edward Tenthoff
Boost Price TargetOverweight$72.00 ➝ $80.00
11/26/2019S&P Equity Research
Reiterated RatingBuy
10/17/2018William Blair
Reiterated RatingOutperform
(Data available from 8/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.